For research use only. Not for therapeutic Use.
PM-43I（Cat No.:I034895）is an investigational small molecule compound that acts as a selective inhibitor of certain protein kinases involved in cell signaling, including those associated with cancer and inflammatory diseases. By targeting these kinases, PM-43I aims to disrupt critical pathways that regulate cell growth, survival, and inflammation. It is being studied for its potential therapeutic applications in treating various cancers and conditions characterized by dysregulated kinase activity, such as autoimmune disorders. Currently undergoing preclinical and early clinical evaluations, PM-43I holds promise as a targeted treatment option for these diseases.
| CAS Number | 1637532-77-4 |
| Synonyms | [[difluoro-[4-[(E)-4-[[(3S)-1-[2-(N-methylanilino)-2-oxoethyl]-2-oxoazepan-3-yl]amino]-4-oxobut-2-en-2-yl]phenyl]methyl]-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate |
| Molecular Formula | C38H50F2N3O10P |
| Purity | ≥95% |
| IUPAC Name | [[difluoro-[4-[(E)-4-[[(3S)-1-[2-(N-methylanilino)-2-oxoethyl]-2-oxoazepan-3-yl]amino]-4-oxobut-2-en-2-yl]phenyl]methyl]-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate |
| InChI | InChI=1S/C38H50F2N3O10P/c1-26(22-31(44)41-30-16-12-13-21-43(33(30)46)23-32(45)42(8)29-14-10-9-11-15-29)27-17-19-28(20-18-27)38(39,40)54(49,52-24-50-34(47)36(2,3)4)53-25-51-35(48)37(5,6)7/h9-11,14-15,17-20,22,30H,12-13,16,21,23-25H2,1-8H3,(H,41,44)/b26-22+/t30-/m0/s1 |
| InChIKey | MUOJHRIQZPVHNP-ZLMUDAIHSA-N |
| SMILES | C/C(=C\C(=O)N[C@H]1CCCCN(C1=O)CC(=O)N(C)C2=CC=CC=C2)/C3=CC=C(C=C3)C(F)(F)P(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C |
